University of Lynchburg DMSc Doctoral Project Assignment Repository
Specialty
Emergency Medicine
Advisor
Dr. Nancy Reid
Abstract
As of 2018, Truvada® has been considered the only treatment for PrEP®, and the only medication used to prevent the transmission of the Human Immunodeficiency Virus (HIV); until the United States Food and Drug Administration (FDA) approved Descovy® as a second medication in 2019. While the research dictates the efficacy of Descovy® to be up to par with Truvada®, Descovy® may actually be more beneficial to certain patients in certain scenarios. While the goal is to move forth with a medication that provides better outcomes and an overall decrease in side effects, further research is necessary to determine which of the two is by far superior.
Recommended Citation
Giron EA. The New Era of PrEP: Using Descovy as First Line Treatment. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2021; 3(2).
Restricted
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.